12 / 40
0
0.6
0.8
0.9
0
0.1
0.2
0.3
0.4
0.5
0.7
1.0
3
6
9
12
15
18
Probability of
progression-free survival
Time from randomization (months)
HR 0.35
(95% CI, 0.25–0.49)
P
<0.00001
Randomized treatment
Placebo
Olaparib 400 mg bid monotherapy
8.4 mos
4.8 mos
Ledermann J
et al
.
N Engl J Med
2012
Maintenance with
Olaparib in all comers
Phase II Study 19: PFS